Hims stock rallies on Canaccord’s $40 price target, Street-high call eciks.org
Hims stock rallies on Canaccord’s $40 price target, Street-high call eciks.org
Related reading: CMS goes live with GLP-1 Bridge program for Part D beneficiaries, Pep Club Launches Telehealth Platform Combining Prescription Therapy, Peptide Protocols, and At-Home Biomarker Testing, Medicare covers weight-loss drugs for $50 a month starting July 1, Doctors warn GLP-1 users about dehydration risk amid severe heat.